Intralesional interferon alfa-2b treatment of keratoacanthomas - 24/08/11
, Hyo-Sung Son, MD, Jae-Bong Lee, MD, Ho-Sun Jang, MD, PhD, Kyung-Sool Kwon, MD, PhD
Reprint requests: Chang-Keun Oh, MD, PhD, Department of Dermatology, Pusan National University College of Medicine, 1-10 Ami-dong, Seo-gu, Busan, 602-739, KoreaBusan, Korea
Abstract |
Background |
Complete excision is not always easy when a keratoacanthoma is large or located in certain anatomic areas. An effective nonsurgical treatment would be desirable in such cases.
Objective |
This was a pilot study of the effects of intralesional interferon alfa-2b in the treatment of rapidly growing keratoacanthomas.
Methods |
A total of 4 large, rapidly growing keratoacanthomas, which were located on the lower lip, neck, and cheeks of the 4 different patients, were treated with intralesional interferon alfa-2b injection weekly. Serial photographs were taken to observe the course of responses.
Results |
All lesions resolved completely in 5 to 7 weeks with acceptable cosmetic results.
Conclusion |
Intralesional interferon alfa-2b can be a treatment modality of these difficult lesions.
Le texte complet de cet article est disponible en PDF.Plan
| The pagination of this article was incorrect as originally published (2004:51;S105-S108). Please use the corrected page numbers listed online at http:www.eblue.org, in the corrected table of contents, or in the December 2004 index in future citations. This supplement is made possible through the generous support of Stiefel Laboratories for the American Academy of Dermatology. Funding sources: None. Conflicts of interest: None identified. |
Vol 51 - N° 5S
P. S177-S180 - novembre 2004 Retour au numéro
Article précédent
- Deep dermatophytosis caused by Trichophyton rubrum with concomitant disseminated nocardiosis in a renal transplant recipient
- Deniz Seçkin, Sevtap Arıkan, Mehmet Haberal
- Pelodera strongyloides infestation presenting as pruritic dermatitis
- Akio Tanaka, Maiko Kinoshita, Toshihiko Tanaka, Yuzuru Iwanaga, Noboru Kagei, Michihiro Hide
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?